Flavonoid compound as well as preparation method and application thereof

By extracting and identifying anti-MRSA activity flavonoids from erythropods, the problem that erythropods flavonoids in the prior art has not been studied, and its antibacterial to methicillin-resistant Staphylococcus aureus was verified. The role has laid the foundation for the development of new anti-MRSA drugs.

CN118908927AActive Publication Date: 2024-11-08ORDOS MONGOLIAN MEDICINE HOSPITAL (ORDOS MONGOLIAN MEDICINE RES INST)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410962615.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08
Estimated Expiration
2044-07-17

AI Technical Summary

Technical Problem

MRSA is resistant to antibiotics, making treatment difficult to control. The existing research mainly focuses on volatile oils of red oxids. No antibacterial activity of its flavonoid components has been reported, and there is a lack of effective low-toxic anti-MRSA drugs.

Method used

8,2′-diisopentylquercetin-3-methyl ether and 8-isoisometric were extracted and identified from erythrocytes by ethanol ultrasonic extraction, silica gel column gradient elution and high performance liquid chromatography column separation. Flavonoid compounds such as pentenyl kaempferol have been verified to have antibacterial effects on methicillin-resistant Staphylococcus aureus.

Benefits of technology

The inhibitory effects of 8,2'-diisopentylquercetin-3-methyl ether and 8-isopentyl kaempferol on methicillin-resistant Staphylococcus were determined in order to develop a new type Anti-MRSA drugs provide scientific evidence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908927A_ABST
    Figure CN118908927A_ABST
Patent Text Reader

Abstract

The embodiment of the invention discloses a flavonoid compound as well as a preparation method and application thereof. 8, 2 '-diisopentenyl quercetin-3-methyl ether and 8-isopentenyl kaempferol, which are separated from a thladiantha dubia extract, have a relatively good inhibition effect on methicillin-resistant staphylococcus, and are used for clinical treatment of methicillin-resistant staphylococcus infection, and the active ingredient 8, 2'-diisopentenyl quercetin-3-methyl ether and 8-isopentenyl kaempferol of the thladiantha dubia can be used for preparing a medicine for treating methicillin-resistant staphylococcus infection. According to the invention, a better scientific basis is provided for development and utilization of 2, 2 '-diisopentenyl quercetin-3-methyl ether and 8-isopentenyl kaempferol.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The embodiments of the present invention relate to the field of biotechnology, and specifically to a flavonoid compound and a preparation method and application thereof. Background Art

[0002] MRSA is one of the most common causes of multidrug-resistant infections, with significant morbidity and mortality, and has become one of the important pathogens of hospital-acquired and community-acquired infections. As MRSA gradually develops resistance to all types of antibiotics, it becomes increasingly difficult to control. Therefore, it is of great significance to seek low-toxic and effective therapeutic drugs. Find new drugs to fight MRSA. Mongolian medicine has a wide range of efficacy and few toxic and side effects. It is one of the four major ethnic medicines in my country. In the process of treating infections, Mongolian medicine can not only play an antibacterial role by directly inhibiting bacterial reproduction or killing bacteria, but also improve the body's immunity and play an anti-infection role. However, due to the extremely complex chemical composition and numerous pharmacological mechanisms of Mongolian medicine, the understanding of the mutual connection between the multiple targets of Mongolian medicine is not in-depth, and the research progress is relatively slow, so it is of great significance to screen and identify its active ingredients.

[0003] Chilangzi is the dried mature fruit of Thladiantha dubiaBge, a plant of the Cucurbitaceae family. It is a commonly used clinical medicine in Mongolian medicine. Its Mongolian name is Aolemosel. It has the effects of promoting blood circulation and removing blood stasis, regulating menstruation, and is mainly used for vaginal diseases, blood stasis in the uterus, blood stasis, amenorrhea, blood vessel diseases, skin diseases, stillbirth, retained placenta, etc. In addition, domestic and foreign scholars have found that Chilangzi has antioxidant, analgesic and anti-inflammatory effects. Kang Yan et al. found that the main active ingredient of Chilangzi's anti-inflammatory and analgesic effects is total organic acid. In recent years, Zhang Xing et al. found that the volatile oil of Chilangzi has significant antibacterial effects on Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Acinetobacter baumannii, Paratyphoid A, Paratyphoid B and other bacteria.

[0004] At present, the research on the antibacterial components of red croton seeds mostly involves volatile oils, and no research on the antibacterial activity of red croton seeds flavonoids has been reported. Summary of the invention

[0005] To this end, the embodiments of the present invention provide a flavonoid compound and a preparation method and application thereof. This paper studies the anti-MRSA activity of red croton seeds and its active ingredients. By using an activity tracking method, substances with anti-MRSA activity are extracted and separated from red croton seeds, in order to lay a foundation for the development of new anti-MRSA drugs.

[0006] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:

[0007] According to a first aspect of an embodiment of the present invention, the present invention provides a flavonoid compound having the following structural formula:

[0008]

[0009] According to the second aspect of an embodiment of the present invention, the present invention provides a method for preparing the flavonoid compounds as described above, the method comprising: using ethanol as a solvent, ultrasonically extracting the crushed red jujube seeds, filtering, and concentrating, gradient eluting the obtained crude extract using a silica gel chromatography column, and then separating it using a high performance liquid chromatography column.

[0010] Furthermore, the concentration of the ethanol is 95%, the red mulberry seeds are crushed into 24-mesh coarse powder, and the solid-liquid ratio is 1:5; the power of the ultrasonic extraction is 500w, the time is 30min, and the number of extractions is 3 times.

[0011] Furthermore, the silica gel chromatography column is gradient eluted with petroleum ether-ethyl acetate at a volume ratio of 50:1, 20:1, 15:1, 10:1, 5:1, and 3:1;

[0012] The high performance liquid chromatography column uses an acetonitrile-trifluoroacetic acid water system with a volume ratio of 60%:40% as a mobile phase, wherein the trifluoroacetic acid water is composed of water and trifluoroacetic acid with a volume ratio of 1000:0.1.

[0013] According to a third aspect of the embodiments of the present invention, the present invention provides use of the flavonoid compound as described above in the preparation of an anti-methicillin-resistant Staphylococcus aureus drug.

[0014] Furthermore, the anti-methicillin-resistant Staphylococcus aureus drug is a medicament prepared by taking the flavonoid compound or its salt as an active ingredient and adding pharmaceutically acceptable excipients.

[0015] The embodiments of the present invention have the following advantages:

[0016] This paper takes the Mongolian medicine Chilangzi as the research object, and screens and identifies its antibacterial active ingredients. First, four compounds were isolated from the extract of Chilangzi, and the structures of these compounds were determined by modern spectral technology combined with physical and chemical methods. Secondly, the minimum inhibitory concentration (MIC) of monomer compounds and antibacterial drugs was determined with reference to the microbroth dilution method recommended by CLSI. The results showed that 8,2′-diisopentenylquercetin-3-methyl ether and 8-isopentenylkaempferol had antibacterial effects on methicillin-resistant Staphylococcus, with MICs of 32μg / ml and 16μg / ml, respectively. The above results fully confirm that the active ingredients in the ethanol extract of red yam seeds that have inhibitory effects on methicillin-resistant Staphylococcus are 8,2′-diisopentenylquercetin-3-methyl ether and 8-isopentenylkaempferol, which provide a better scientific basis for the clinical treatment of methicillin-resistant Staphylococcus infection and the development and utilization of the active ingredients of red yam seeds 8,2′-diisopentenylquercetin-3-methyl ether and 8-isopentenylkaempferol. DETAILED DESCRIPTION

[0017] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0018] Example 1

[0019] Preparation and identification of flavonoids

[0020] 1. Materials and Methods

[0021] 1.1 Experimental materials: Chilangzi, Inner Mongolia Yikang Chinese Medicine Pieces Co., Ltd.; MRSA (clinical isolate preserved by the Institute of Microbiology, Chinese Academy of Sciences).

[0022] 1.2 Reagents and instruments: MH medium; PBS (Beijing Hongyue Innovation Technology Co., Ltd.); methanol (chromatographic grade) (Tianjin Siyou Chemical Reagent Company); acetonitrile (chromatographic grade) (Fisher Scientific, ChemAlert); n-hexane (analytical grade) (Beijing Chemical Reagent Company); ethyl acetate, dichloromethane, acetone, methanol, ethanol, dimethyl sulfoxide (analytical grade, Beijing Chemical Reagent Company). Bruker Avance 500MHz NMR; Agilent 6520LC / MS high-resolution mass spectrometer; Bruker Esquire 3000plus low-resolution mass spectrometer; Agilent 1200 high-performance liquid chromatograph; RP-C18 chromatographic analysis column 150mm×4.6mm (Agilent and YMC); EL800 microplate reader (BIO-TEK, USA); CO2 incubator (Thermo Fisher, USA); Waters 1525 high-performance liquid chromatograph (Waters, USA); 2996 PDA detector; Empower chromatography workstation; Agela Venusil XBP-C18, Agela Company; ACB-4A1 clean bench (Singapore Yisi High Technology Co., Ltd.); electronic analytical balance AL240 (Swiss Mettler, Toledo Instruments); CNC ultrasonic cleaner KQ3200DE (Kunshan Ultrasonic Instrument Co., Ltd.); rotary evaporator RE-52AA (Shanghai Yarong Biochemical Instrument Factory). Column chromatography silica gel, thin layer chromatography silica gel GF254, thin layer chromatography silica gel HG / T2354-92, Sephadex LH-20 (Fluka Company, USA) column chromatography silica gel (Qingdao Ocean Chemical Co., Ltd.); color developer 10% H2SO4-ethanol solution (homemade).

[0023] 1.3 Experimental methods:

[0024] 1.3.1 Preparation of the extract of red hyacinth seed: the medicinal material was crushed and passed through a 24-mesh sieve. The coarse powder was treated with 95% ethanol as solvent, solid-liquid ratio (1:5), ultrasonic extraction time (500w, 30min), extraction times (3 times), and the filtrates were combined, vacuum concentrated, and freeze-dried.

[0025] 1.3.2 Separation of the extract of the red jujube: The crude extract was separated by silica gel column chromatography, and gradient elution with petroleum ether-ethyl acetate (volume ratio: 50:1, 20:1, 15:1, 10:1, 5:1, 3:1) was used to obtain 42 fractions (Fr.1-42). After high performance liquid chromatography (60% acetonitrile-trifluoroacetic acid water, wherein the trifluoroacetic acid water consists of water and trifluoroacetic acid in a volume ratio of 1000:0.1), 4 compounds were prepared.

[0026] 2 Results

[0027] 2.1 Compound isolation and structural identification: Four compounds were isolated from the extract of the fruit of the Chinese yam. The structures of the four compounds were determined using modern spectral technology combined with physical and chemical methods. They are 8,2′-diisopentenylquercetin-3-methyl ether (compound 1), deoxypodophyllotoxin (compound 2), yatein (compound 3), and 8-isopentenylkaempferol (compound 4).

[0028]

[0029] Compound 1: yellow powder (MeOH), HCl-Mg reaction is positive. HR-ESI-MS m / z: 453.1912 [M+H] + (calc.453.1908). 1 H NMR(CDCl3,500MHz)δ6.37(1H,s,H-6),6.88(1H,d,J=8.3Hz,H-6′),6.86(1H,d,J=8.3Hz,H-5′),3.40(4H,m,H-1″and H-1″′),5.16(2H,m,H-2″and H-2″′), 1.61(3H,d,J=1.4Hz,H-4″), 1.60(3H,d,J=1.4Hz,H-5″), 1.54(3H,s,H-4″′), 1.64(3H,d,J=1.4Hz,H-5″′), 3.63(3H,s,-OCH3). 13 C NMR(MeOD,125MHz)δ161.9(C-1),140.4(C-3),180.4(C-4),160.8(C-5),99.2(C-6),163.1(C- 7),107.9(C-8),156.3(C-9),106.3(C-10),123.3(C-1′),129.5(C-2′),144.7(C-3′),148.3(C -4′),113.1(C-5′),122.5(C-6′),22.4(C-1″),123.4(C-2″),132.4(C-3″),17.7(C-4″),25.7( C-5″), 26.6(C-1″′), 124.2(C-2″′), 132.1(C-3″′), 17.8(C-4″′), 26.0(C-5″′), 60.9(-OCH3).

[0030] Compound 2: white solid. HR-ESI-MS m / z: 399.1446 [M+H] + (calcd.for C 22 H23 O7,399.1444). 1 1H-NMR (500 MHz, CD3OD) δ 6.71 (1H, s, H-6), 6.45 (1H, s, H-3), 6.38 (2H, s, H-2', 6'), 5.90 (2H, d, J = 2.4 Hz, -OCH2O-), 4.57 (1H, d, J = 4.8 Hz, H-7'), 4.44 (1H, dd, J = 8.4, 6.9 Hz, H-9a), 3.96 (1H, dd, J = 9.6, 8.4 Hz, H-9b), 3.71 (6H, s, 3',5'-OCH3), 3.70 (3H, s, 4'-OCH3), 3.08 (1H, dd, J = 14.3, 4.8 Hz, H-7b), 2.88 (1H, dd, J = 14.3, 4.8 Hz, H-7a), 2.75 (2H, m, H-8, 8'); 13 13C-NMR (125 MHz, CD3OD) δ 177.7 (C-9'), 153.7 (C-3', 5'), 148.5 (C-5), 148.1 (C-4), 138.6 (C-1', 4'), 132.0 (C-2), 130.4 (C-1), 111.1 (C-3, 6), 109.5 (C-2', 6'), 102.5 (-OCH2O-), 73.6 (C-9), 61.1 (4'-OCH3), 56.5 (3', 5'-OCH3), 48.3 (C-8'), 45.0 (C-7'), 34.4 (C-8), 33.6 (C-7).

[0031] Compound 3: Colorless oil. ESI-MS m / z: 401 [M+H] + , C 22 H 24 O7. 1 1H NMR (MeOD, 500 MHz, δ, ppm, J / Hz): 6.81 (1H, d, J = 7.6, H-5), 6.68 (1H, d, J = 1.6, H-2), 6.58 (1H, dd, J = 7.6, 1.6, H-6), 6.51 (2H, s, H-2′, 6′), 5.98 (2H, dd, J = 4.4, 1.2, -OCH2O-), 4.16 (1H, m, H-9a), 3.92 (1H, m, H-9b), 3.64–3.76 (9H, s, 3′, 4′, 5′-OCH3), 2.76 (2H, m, H-7′), 2.44–2.56 (4H, m, H-7, 8, 8'). 13C NMR(MeOD,125MHz,δ,ppm):181.3(C-9′),154.5(C-3′,5′),149.3(C-3),14 7.7(C-4),137.8(C-4′),135.5(C-1′,133.7(C-1),122.8(C-6),110.0(C-2 ),109.1(C-5),107.7(C-2′,6′),102.3(-OCH2O-),72.9(C-9),61.1(4′-OC H3),56.6(3′,5′-OCH3),47.7(C-8′),42.5(C-8),39.1(C-7),36.1(C-7′).

[0032] Compound 4: yellow amorphous powder (methanol). ESI-MS m / z: 377.1 [M+Na] + , molecular formula is C 20 H 18 O6. 1 H-NMR(500MHz,CD3OD)δ:6.23(1H,s,H-6),8.10(2H,d,J=9.0Hz,H-2′,6′),6.90(2H,d,J=9.0Hz,H- 3′,5′),3.50(2H,m,H-1″),5.22(1H,t,J=7.6Hz,H-2″),1.80(3H,s,4″-CH3),1.67(3H,s,5″-CH3); 13 C-NMR (125MHz, CD3OD) δ: 148.0 (C-2), 137.0 (C-3), 177.6 (C-4), 160.1 (C-5), 98.7 (C-6), 162.8 (C-7), 107.6 (C-8), 160.1 (C-9), 104.5 (C -10),124.0(C-1′),130.5(C-2′,6′),116.3(C-3′,5′),155.5(C-4′),22.4(C-1″),123.9(C-2″),132.4(C-3″),25.9(C-4″),18.2(C-5″).

[0033] Example 2

[0034] Antibacterial activity test

[0035] 1. Materials and Methods

[0036] 1.1 Sample preparation

[0037] The compound and antibacterial drug were prepared into a solution with a mass concentration of 1.28 mg / mL using DMSO solution, filtered with a 0.22 μm microporous filter membrane, and compound 1-4 was diluted with liquid culture medium in a series of mass concentrations of 32, 16, 8, 4, 2, and 1 μg / mL. The antibacterial drug vancomycin (Van) was diluted with liquid culture medium in a series of mass concentrations of 16, 8, 4, 2, 1, 0.5, and 0.25 μg / mL. The antifungal drug amphotericin B (Amph-B) was diluted with liquid culture medium in a series of mass concentrations of 40, 20, 10, 5, 2.5, 1.25, and 0.625 μg / mL.

[0038] 1.2 Preparation of test bacterial solution

[0039] Taking Staphylococcus aureus as an example, the bacterial suspension stored in -80℃ glycerol was dissolved at 37℃, and the bacterial suspension was inoculated on the TSA plate by the three-zone "Z-shaped" streak method using a disposable inoculation loop in the clean bench for recovery, and cultured in a 37℃ incubator for 16 hours; a single colony was dipped into a turbidimetric tube with an inoculation loop, and calibrated to a 0.5 McFarland turbidimetric standard (concentration of about 10 8 CFU / mL); then diluted with TSB medium at a ratio of 1:100 to about 5×10 5 CFU / mL, as the test bacterial solution.

[0040] Staphylococcus aureus (MRSA) was cultured in TSB medium, EAEC (enterohemorrhagic Escherichia coli) was cultured in LB medium, PA (Pseudomonas aeruginosa) was cultured in LB medium; Candida albicans was cultured in 1640 medium; Aspergillus fumigatus was cultured in PDB medium.

[0041] 1.3 Minimum inhibitory concentration determination:

[0042] With reference to the CLSI-recommended microbroth dilution method, a total of five pathogenic bacteria were used to determine the minimum inhibitory concentration (MIC) of monomer compounds and antimicrobial drugs. The minimum antimicrobial concentration in the sterile growth well is the MIC, based on whether the broth in the microwell is turbid and whether there is precipitation at the bottom of the well.

[0043] 2 Results

[0044] 2.1 Antimicrobial activity

[0045] The antibacterial activity results are shown in Table 1: Compounds 1 and 4 have good antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), and the antibacterial activity of compound 4 is greater than that of compound 1. They have no antibacterial activity against other bacteria, while compounds 2 and 3 have no antibacterial activity against all five strains.

[0046] Table 1 Antibacterial activity screening results of compounds 1 to 4 (MIC, μg ml -1 )

[0047]

[0048]

[0049] Note: The positive control for Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus is vancomycin; the positive control for Candida albicans and Aspergillus fumigatus is amphotericin B.

[0050] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A flavonoid compound, characterized in that: The flavonoid compound has the following structural formula:

2. The method for preparing flavonoid compounds according to claim 1, characterized in that: The method comprises: using ethanol as solvent, ultrasonically extracting the crushed red schizonepeta, filtering, concentrating, gradient eluting the obtained crude extract with a silica gel chromatography column, and then separating with a high performance liquid chromatography column.

3. The method for preparing flavonoid compounds according to claim 2, characterized in that: The concentration of the ethanol is 95%, the red mulberry seeds are crushed into 24-mesh coarse powder, and the solid-liquid ratio is 1:5; The power of the ultrasonic extraction is 500w, the time is 30min, and the number of extractions is 3 times.

4. The method for preparing flavonoid compounds according to claim 2, characterized in that: The silica gel chromatography column was gradient eluted with petroleum ether-ethyl acetate at a volume ratio of 50:1, 20:1, 15:1, 10:1, 5:1, and 3:1; The high performance liquid chromatography column uses an acetonitrile-trifluoroacetic acid water system with a volume ratio of 60%:40% as a mobile phase, wherein the trifluoroacetic acid water is composed of water and trifluoroacetic acid with a volume ratio of 1000:0.

1.

5. Use of the flavonoid compound according to claim 1 in the preparation of an anti-methicillin-resistant Staphylococcus aureus drug.

6. The use according to claim 5, characterized in that: The anti-methicillin-resistant Staphylococcus aureus drug is a medicament prepared by taking the flavonoid compound or its salt as an active ingredient and adding pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Fructus Podophylli extract and application thereof

    CN101647842A

  • Momordica grosvenori new flavonoid compound, preparation method thereof and application of momordica grosvenori new flavonoid compound in bee attractant

    CN114516893A

  • Anti-oxidative or Anti-inflammatory composition comprising extract from leaves of corylopsis coreana.uyeki or phenolic compounds isolated from the same

    KR1020130086448A